Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-04-12
2005-04-12
Weber, Jon (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C530S380000, C530S381000, C530S395000, C930S010000, C930S250000
Reexamination Certificate
active
06878813
ABSTRACT:
The present invention discloses modified antithrombin III compounds and methods. The amino acid compounds of the present invention are useful in treating blood clotting disorders, as well as other disease states associated with enzymes in the coagulation pathway.
REFERENCES:
patent: 5204253 (1993-04-01), Sanford et al.
patent: 5420252 (1995-05-01), Kato et al.
patent: 5618713 (1997-04-01), Zettlmeissl
patent: 5700663 (1997-12-01), Zettlmeissl et al.
patent: 5843705 (1998-12-01), DiTullio et al.
patent: 0 568 833 (1993-08-01), None
patent: WO 9100291 (1991-01-01), None
patent: WO 9505853 (1995-03-01), None
patent: WO 9519799 (1995-07-01), None
Cunningham et al. Development of an Elastase-Resistant antithrombin through mutagenesis at P4. (1995) Blood 86(10) SUPP p. 357A.*
Cunningham et al. Development of an Elastase-Resistant antithrombin through mutagenesis at P4. (1995) Blood 86(10) SUPPL. p. 357A.*
Blauhut et al. “Substitution of antithrombin III in shock and DIC: a randomized study.” Thromb Res. Jul. 1, 1985;39(1):81-9.
Buller and ten Cate, “Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate.” Am J Med. Sep. 11, 1989;87(3B):44S-48S.
Damus and Wallace, “Immunologic measurement of antithrombin III-heparin cofactor and α2-macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy.” Thromb Res. Jan. 1975;6(1):27-38.
Delshammar et al. “Abnormal proteolysis (DIC)—successful treatment with antithrombin III concentrate and a concentrate containing F XIII and native von Willebrand factor.” J Intern Med. Jan. 1989;225(1):21-7.
Dickneite and Paques, “Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis.” Thromb Haemost. Feb. 1, 1993;69(2):98-100, 102.
Emerson et al. “Efficacy of antithrombin III supplementation in animal models of fulminantEscherichia coliendotoxemia or bacteremia.” Am. J. Med. Sep. 11, 1989;87(3B):27S-33S.
Ersdal-Badju et al. Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a β-like variant in baculovirus-infected insect cells. Biochem. J. Aug. 15, 1995;310:323-30.
Fourrier et al. “Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation.” Chest. Sep. 1993;104(3)882-8.
Franzen et al. “Structural Studies on the Carbohydrate Portion of Human Antithrombin III.” J. Biol. Chem. Jun. 10, 1980;255(11):5090-3.
Hedin et al. “Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells.” Arterioscler Thromb. Feb. 1994;14(2):254-60.
Hellgren et al. “Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients.” Intensive Care Med. 1984;10(1):23-8.
Hellgren et al. “Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients.” Thromb Res. Aug. 15, 1984;35(4):459-66.
Jochum, “Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation.” Semin Hematol. Oct. 1995;32(4 Suppl 2):19-32.
Kurachi et al. “Inhibition of Bovine Factor IXaand Factor Xaβby Antithrombin III.” Biochemistry Jan. 27, 1976;15(2):373-7.
Lammle et al. “Plasma prekallikrein, factor XII, antithrombin III, C1-inhibitor and α2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC).” Am J Clin Pathol. Oct. 1984;82(4):396-404.
Lawson et al. “Complex-dependent inhibition of factor VIIa by antithrombin III and heparin.” J. Biol. Chem. Jan. 15, 1993: 268(2):767-70.
Mammen et al. “Human antithrombin concentrates and experimental disseminated intravascular coagulation.” Semin Thromb Hemost. Oct. 1985;11(4):373-83.
Mant et al. “Haemorrhagic complications of heparin therapy.” Lancet. May 28, 1977;1(8022):1133-5.
Marcum et al. “Microvascular heparinlike species with anticoagulant activity.” Am. J. Physiol. Nov. 1983;245(5 Pt 1):H725-33.
Mizuochi et al. “Structural studies of the carbohydrate moiety of human antithrombin III.” Arch Biochem Biophys. Aug. 1980;203(1):458-65.
Nuijens et al. “Plasma elastase α1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis.” J Lab Clin Med. Feb. 1992;119(2):159-68.
Ostrovsky et al. “Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion.” Circulation. Oct. 1997;96(7):2302-10.
Petersen et al.The Physiological Inhibitors of Coagulation and Fibrinolysis. 43-54. Elsevier/North Holland Biomedical Press (1979).
Peterson and Blackburn, “Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding.” J. Biol. Chem. Jan. 10, 1985;260(1):610-5.
Picard and Bock,Methods in Molecular Biology, vol. 67:PCR Cloning Protocols: From Molecular Cloning to Genetic Engineering. 183-8. B. A. White Humana Press Inc., Totowa, NJ (1996).
Picard et al. “A rapid and efficient one-tube PCR-based mutagenesis technique usingPfuDNA polymerase.” Nucleic Acids Res. Jul. 11, 1994;22(13):2587-91.
Rao et al. “Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa.” Blood. May 15, 1993;81(10):2600-7.
Rosenberg and Damus, “The purification and mechanism of action of human antithrombin-heparin cofactor.” J. Biol. Chem. Sep. 25, 1973;248(18):6490-505.
Rosenberg, “Chemistry of the hemostatic mechanism and its relationship to the action of heparin.” Fed Proc. Jan. 1977;36(1):10-8.
Ruf and Mueller,“Tissue factor in cancer angiogenesis and metastasis.” Curr Opin Hematol. Sep. 1996;3(5):379-84.
Seitz et al. “Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections.” Eur J Haematol. Mar. 1987;38(3):231-40.
Uchiba and Okajima, “Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: novel biological activity of AT III.” Semin Thromb Hemost. 1997;23(6):583-90.
Van Boven and Lane, “Antithrombin and its inherited deficiency states.” Semin Hematol. Jul. 1997;34(3):188-204.
Wolff et al. “Direct gene transfer into mouse muscle in vivo.” Science Mar. 23, 1990;247(4949 PT 1):1465-8.
Zendehrouh, “Novel proteinase inhibitors for use in the treatment of sepsis.”Dissertation submitted to the Temple University Graduate Board, 165 pages (May 1998).
Bock et al,10 Nucleic Acids Res.8113 (1982) .
Jochum et al,362 Hoppe-Seyler's Z. Physiol. Chem.103 (1981).
Carrell and Owen,317 Nature730 (1985).
Jordan et al,237 Science777 (1987).
Bick et al,73 Am. J. Clin. Path.577 (1980).
Vinazzer,1 Clin. Appl. Thrombosis/Hemostasis62 (1995).
Brennan et al.,219 FEBS Lett.431 (1987).
Picard et al,34 Biochemistry8433 (1995).
Cunningham et al,88 Thrombsis Res171 (1997).
69thScientific Sessions. Abstract No. 4336, Kato et al. ‘Recombinant Antithrombin III Mutants with Enhanced Antithrombin Activity without Heparin.’ 1996, vol. 94, No. 8 suppl., p. I-741.
Stephens, et al. Site-directed Mutagenesis of the Reactive Center (Serine 394) of Antithrombin III. J. Biol. Chem. Nov. 5, 1988, vol. 263, No. 31, pp. 15849-15852.
Owen et al. “P1 variant antithrombins Glasgow (393 Arg to His) and Pescara (393 Arg to Pro) have increased heparin affinity and are resistant to catalytic cleavage by elastase” 380(2)216-220, Mar. 1991.
Bock Susan C.
Picard Veronique
Zendehrouh Pedram
Needle & Rosenberg P.C.
Schnizer Holly
Temple University - of the Commonwealth System of Higher Educati
University of Utah Research Foundation
Weber Jon
LandOfFree
Human antithrombin IIIs and methods related thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human antithrombin IIIs and methods related thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human antithrombin IIIs and methods related thereto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3407610